A pioneering team of physician-scientists has been awarded the prestigious Breakthrough Prize in Life Sciences for developing the first FDA-approved gene therapy for an inherited disease, a treatment that restores vision to people with a specific form of congenital blindness.
The award recognizes decades of work by Jean Bennett, Albert Maguire, and Katherine High, whose collaboration led to Luxturna (voretigene neparvovec). This therapy treats Leber Congenital Amaurosis (LCA) caused by mutations in the RPE65 gene. People born with this mutation have severely impaired vision from birth and often progress to complete blindness. The therapy works by using a modified, harmless virus as a vector to deliver a functional copy of the RPE65 gene directly into retinal cells, correcting the underlying genetic defect and enabling the production of proteins essential for sight.
The journey began with research on a group of blind dogs at the University of Pennsylvania's School of Veterinary Medicine, which had a condition nearly identical to human LCA. After successful trials in these dogs showed dramatic visual recovery, the team, with critical manufacturing and clinical support from the Children's Hospital of Philadelphia, launched human trials. In 2007, the first patient received the experimental injection. Results from the pivotal trials were transformative: 72 percent of participants achieved the maximum possible improvement in a test simulating night vision. Anecdotal outcomes were profound, with one previously light-perception-only patient gaining the ability to navigate city streets at night and another seeing a star for the first time.
The 2017 FDA approval of Luxturna marked a historic milestone, validating gene therapy as a viable treatment for genetic disorders. Its success has paved the way for an explosion of research, inspiring more than 140 subsequent gene therapy trials for retinal conditions like macular degeneration and diabetic retinopathy, which affect tens of millions. The award underscores the therapy's role as a trailblazer for the entire field of genetic medicine.
Looking forward, the recognition of this team highlights the potential of persistent, foundational science to overcome what once seemed impossible. The principles and viral vector delivery methods honed in the development of this therapy continue to inform new treatments for a wide range of genetic diseases, offering a hopeful template for turning once-futuristic concepts into life-changing clinical realities.